|Day Low/High||2.42 / 2.64|
|52 Wk Low/High||2.05 / 7.00|
PlasmaTech Biopharma (PTBI) stock is up after the company had coverage initiated by analysts at Roth Capital with a 'buy' rating.
PlasmaTech Biopharmaceuticals (PTBI) shares are gaining after the company announced the licensing of its juvenile Batten Disease treatment candidate.
PlasmaTech Biopharmaceuticals is enjoying a higher profile now that the business community is paying more attention to rare disease treatments, said the company's CEO Tim Miller.
PlasmaTech Biopharmaceuticals (PTBI) shares are climbing after the company had coverage initiated with a 'buy' rating and a $15 price target.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.